BUKWANG PHARMACEUTICAL IND CO.,LTD (부광약품(주))
KOSPI Stock Code: 003000 | DART Corp Code: 00123718
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | BUKWANG PHARMACEUTICAL IND CO.,LTD |
|---|---|
| Korean legal name | 부광약품(주) |
| Alternate names | 부광약품 |
| Market | KOSPI |
| Stock Code | 003000 |
| DART Corp Code | 00123718 |
| CEO | 이제영 |
| Business Registration No. | 1188100450 |
| Corporate Registration No. | 1101110030405 |
| Established Date | 1960-10-17 |
| Fiscal Month | 12 |
| KSIC Industry Code | 212 |
| Address (KO) | 서울특별시 동작구 대방동1길 47 |
| Homepage | https://www.bukwang.co.kr/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001273 |
| verified_at | 2026-11-01T02:17:00.639Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001273
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 200,714,183,691 | KRW 160,086,870,107 |
| Operating Income (영업이익) | KRW 14,163,801,286 | KRW 1,617,661,424 |
| Net Income (당기순이익) | KRW 12,433,079,755 | KRW -3,458,761,838 |
| Total Assets (자산총계) | KRW 476,294,610,331 | KRW 373,180,311,828 |
| Total Liabilities (부채총계) | KRW 135,362,536,191 | KRW 129,034,731,764 |
| Total Equity (자본총계) | KRW 340,932,074,140 | KRW 244,145,580,064 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-10-23 | 20261023800177 | Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure) | 연결재무제표기준영업(잠정)실적(공정공시) | 부광약품 |
2026-10-15 | 20261015800450 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 부광약품 |
2026-08-31 | 20260831800733 | Court Ruling on Rehabilitation Procedures and Bankruptcies of Invested Companies | 출자법인회생절차및파산관련결정 | 부광약품 |
2026-08-28 | 20260828001406 | Disclosure of Current Status of Large-scale Business Groups [Quarterly Disclosure (For individual company)] | 대규모기업집단현황공시[분기별공시(개별회사용)] | 부광약품 |
2026-08-26 | 20260826800391 | Decision on Acquisition of Tangible Assets | 유형자산취득결정 | 부광약품 |
2026-08-14 | 20260814800232 | Application for Rehabilitation Procedures and Bankruptcies of Invested Companies | 출자법인회생절차및파산관련신청 | 부광약품 |
2026-08-13 | 20260813001685 | Matters concerning payment amount for each payment method-payment period and Dispute Resolution Organization | 지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 | 부광약품 |
2026-08-13 | 20260813001667 | Semi-annual Report (2026.06) | 반기보고서 (2026.06) | 부광약품 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001273 | verified_at: 2026-11-01T02:17:00.639Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.